Stifel Nicolaus Issues Positive Forecast for TransMedics Group (NASDAQ:TMDX) Stock Price

TransMedics Group (NASDAQ:TMDX) had its price objective upped by analysts at Stifel Nicolaus from $115.00 to $130.00 in a report issued on Monday,Benzinga reports. The brokerage currently has a “hold” rating on the stock. Stifel Nicolaus’ price objective points to a potential upside of 0.15% from the stock’s current price.

A number of other equities analysts also recently commented on the stock. Wall Street Zen downgraded shares of TransMedics Group from a “buy” rating to a “hold” rating in a research note on Saturday, February 28th. Oppenheimer upped their target price on shares of TransMedics Group from $150.00 to $175.00 and gave the company an “outperform” rating in a research note on Wednesday, February 25th. Canaccord Genuity Group raised their price target on shares of TransMedics Group from $147.00 to $148.00 and gave the company a “buy” rating in a report on Wednesday, December 17th. Needham & Company LLC boosted their price objective on shares of TransMedics Group from $166.00 to $174.00 and gave the stock a “buy” rating in a report on Wednesday, February 25th. Finally, Morgan Stanley upped their price objective on shares of TransMedics Group from $123.00 to $135.00 and gave the company an “equal weight” rating in a research report on Tuesday, December 2nd. Six investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $152.33.

TransMedics Group Price Performance

TMDX stock opened at $129.80 on Monday. The company has a market cap of $4.45 billion, a PE ratio of 26.49 and a beta of 1.98. The company has a current ratio of 7.14, a quick ratio of 6.59 and a debt-to-equity ratio of 1.06. The stock has a 50-day moving average price of $135.35 and a two-hundred day moving average price of $126.96. TransMedics Group has a 12-month low of $62.23 and a 12-month high of $156.00.

Insider Activity

In related news, CFO Gerardo Hernandez sold 7,236 shares of the business’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $147.21, for a total transaction of $1,065,211.56. Following the completion of the sale, the chief financial officer owned 14,689 shares of the company’s stock, valued at $2,162,367.69. This represents a 33.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Stephanie Lovell sold 1,193 shares of the stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $149.62, for a total value of $178,496.66. Following the completion of the transaction, the director directly owned 2,866 shares of the company’s stock, valued at $428,810.92. This trade represents a 29.39% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 16,205 shares of company stock valued at $2,353,002 over the last three months. Company insiders own 7.00% of the company’s stock.

Institutional Investors Weigh In On TransMedics Group

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Whittier Trust Co. of Nevada Inc. raised its holdings in shares of TransMedics Group by 981.0% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 227 shares of the company’s stock worth $26,000 after purchasing an additional 206 shares in the last quarter. Salomon & Ludwin LLC bought a new stake in shares of TransMedics Group during the 3rd quarter worth $28,000. Harvest Fund Management Co. Ltd acquired a new position in shares of TransMedics Group in the third quarter worth about $29,000. Allworth Financial LP increased its position in shares of TransMedics Group by 74.3% in the third quarter. Allworth Financial LP now owns 265 shares of the company’s stock worth $30,000 after acquiring an additional 113 shares in the last quarter. Finally, Optiver Holding B.V. raised its holdings in shares of TransMedics Group by 248.1% during the third quarter. Optiver Holding B.V. now owns 268 shares of the company’s stock valued at $30,000 after acquiring an additional 191 shares during the period. 99.67% of the stock is owned by institutional investors and hedge funds.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.